Dianthus Therapeutics is expected to report a third-quarter revenue of $0.46 million and a consensus loss per share of $0.94, with the stock currently trading near $82.70 against a bullish average analyst target of $128.54.
Investors are primarily focused on pipeline execution for lead candidate claseprubart (DNTH103), specifically enrollment progress in pivotal Phase 3 trials for CIDP and gMG.
Management is also expected to provide updates on the Phase 2 top-line data timing for MMN, currently anticipated in December 2026.
The company’s substantial $1.2 billion cash position remains a critical factor for investors, as it provides a stable operational runway into 2030 to support its intensifying clinical development programs.